“Retail media networks shouldn’t sell ‘awareness’ or ‘impressions’ or ‘conversion,’” Gray wrote on the social media platform ...
Company AnnouncementEPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for ...
In June 2024, EPKINLY monotherapy was granted accelerated approval by the FDA for the treatment of R/R FL following two or more lines of systemic therapy. With the results from the confirmatory Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback